ArticleFrontiers in immunology2025
LASSO-empowered nomogram integrating nutritional-inflammatory-tumor characteristics predicts immunotherapy outcomes in advanced HCC: Large retrospective cohort.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive Value of Perioperative Systemic Inflammation Response Index Dynamics for Postoperative Pulmonary Infection Following Esophagectomy: A Multicenter Retrospective Cohort Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Immune checkpoint inhibitors (ICIs) show heterogeneous efficacy in advanced hepatocellular carcinoma (HCC), but existing biomarkers are invasive and costly. We aimed to develop a noninvasive prognostic model using routine clinical parameters. Materials and methods: This retrospective study included 537 advanced HCC patients treated with PD-1/PD-L1 inhibitors, randomly divided into training (n=322) and validation (n=215) cohorts. Continuous variables were dichotomized using R packages. Univariate Cox regression followed by LASSO regression with 10-fold cross-validation selected predictive features for nomogram construction. Model performance was assessed via time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Cox proportional hazards models identified independent prognostic factors. Results: Baseline characteristics were balanced between training and validation cohorts (P>0.05). The LASSO-derived nomogram incorporated 13 risk factors, which encompass multiple dimensions such as tumor characteristics, nutritional status, and inflammation. The model demonstrated robust discrimination, with the area under the curve (AUC) values exceeding 0.75 for 3-, 6-, 12-, and 24-month overall survival (OS). Calibration curves demonstrated a strong concordance between the predicted survival probabilities and the actual observations, and DCA revealed that the nomogram could increase net benefit. Additionally, the nomogram successfully stratified patients into low-risk and high-risk groups based on OS risk, with significant survival differences observed between the two groups in both the training and validation cohorts (all p < 0.001). Conclusions: This validated nomogram integrating inflammatory, nutritional, and tumor characteristics provides a cost-effective tool for prognostic stratification in advanced HCC patients undergoing immunotherapy, potentially guiding personalized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.